Acelyrin, INC

ACELYRIN, Inc. has completed its merger with Alumis Inc. on May 21, 2025, resulting in ACELYRIN becoming a wholly-owned subsidiary of Alumis.

ACELYRIN, INC. stockholders voted to approve the merger agreement with Alumis Inc. at a special meeting held on May 13, 2025.

ACELYRIN and Alumis have amended their merger agreement, increasing ACELYRIN stockholders' ownership in the combined company to approximately 48% on a fully diluted basis.

Acelyrin, a clinical biopharma company, adopts a limited-duration stockholder rights plan in response to Tang Capital Partners' increasing stake in the company.

Acelyrin and Alumis have agreed to merge in an all-stock transaction, aiming to create a leading late-stage clinical biopharmaceutical company focused on immune-mediated diseases.

Alumis and ACELYRIN will merge in an all-stock transaction to create a company with a late-stage clinical pipeline targeting immune-mediated diseases.

Acelyrin announces Q1 2025 financial results, including a net loss of $55.3 million, and confirms stockholder approval of the merger with Alumis.

Acelyrin suspends new internal investment in izokibep development, focusing on lonigutamab for thyroid eye disease, while reporting a net loss of $169.2 million for the first nine months of 2024.

Acelyrin reports a net loss of $120.6 million for the first half of 2024 and announces a strategic restructuring to focus on lonigutamab development.

Acelyrin's first quarter 2024 results show a reduced net loss compared to the same period last year, influenced by strategic payments and changes in operating expenses.

Acelyrin's annual report highlights a planned merger with Alumis, a strategic focus on lonigutamab for TED, and a detailed financial overview for 2024.

Acelyrin, Inc.'s 10-K filing outlines the details of its common stock, voting rights, dividend policies, and anti-takeover provisions, as well as key dates and financial metrics.

AyurMaya Capital Management Company, LP and David E. Goel have reported the disposition of over 9.3 million shares of ACELYRIN, Inc. common stock, valued at $0, as a result of the company's merger with Alumis Inc., where each share was converted into 0.4274 shares of Alumis common stock.

ACELYRIN, Inc. Chief Executive Officer Mina Kim's beneficial ownership in the company has been fully converted into Alumis, Inc. equity following the completion of the merger on May 21, 2025.

A recent SEC Form 4 filing reveals the conversion of Director Bruce C. Cozadd's stock options in ACELYRIN, Inc. into Alumis, Inc. shares following the successful merger of the two companies.

ACELYRIN's Chief Legal Officer, Amar Murugan, has reported the conversion of his common stock, restricted stock units, and stock options into Alumis, Inc. securities following the merger of ACELYRIN into Alumis.

ACELYRIN, Inc. Director Beth Seidenberg has reported the disposition of all her direct and indirect holdings of common stock and stock options in ACELYRIN, Inc. as a result of the company's merger with Alumis, Inc. on May 21, 2025.

ACELYRIN, Inc.'s Chief Medical Officer, Shephard Mpofu, has reported the conversion of all his common stock and employee stock options into securities of Alumis, Inc. following the completion of their merger.

Leading proxy advisory firm ISS recommends Acelyrin stockholders vote in favor of the proposed merger with Alumis, citing potential upside and uncertainties surrounding alternatives.

Alumis and ACELYRIN have agreed to merge, forming a combined entity focused on developing transformative medicines, with ACELYRIN stockholders receiving 0.4814 shares of Alumis for each ACELYRIN share.

ACELYRIN urges stockholders to vote in favor of the proposed merger with Alumis, citing significant potential upside and value creation for the combined company.

Alumis and ACELYRIN have agreed to merge in an all-stock transaction, aiming to create a leading biopharmaceutical company with a diversified pipeline.

Acelyrin appoints Mina Kim as CEO, succeeding Shao-Lee Lin, and announces the departure of Chief People Officer Ron Oyston.

ACELYRIN, INC. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.